A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and ...

Steve will be monitoring the Rapid Fires: AI/ML in Bioanalysis session on Monday, Nov. 10, 2025 at 3PM CT at AAPS PharmSci ...

A streamlined workflow using Six Sigma's DMAIC methodology was developed to identify and mitigate visible particles in ...

3D printing technology enables precise drug design, personalized dosing, and versatile release modes, benefiting patient-centric treatments. At AAPS PharmSci 360, Xialing Li, PhD, says 3D-printed ...

In the life sciences industry, the journey from discovery to delivery is only as strong as the supply chain and distribution ...

To learn more about how method validation is performed for biomarker bioanalysis, Pharmaceutical Technology ® spoke with ...

Ex vivo lung perfusion (EVLP) provides a platform for testing therapies but faces challenges in standardizing drug evaluation. At AAPS PharmSci 360, Xuanzi Zhou says digital twins accurately predict ...

Editor's note: this interview was originally published on BioPharmInternational.com.

Two major themes cut across the week’s news: the profound integration of advanced technology, particularly Artificial ...

Tariffs increase operational costs by raising prices for raw materials, APIs, and finished drugs, complicating logistics and ...